In the Phase III TROPION-Breast01 trial (NCT05104866), the efficacy and safety of Dato-DXd were compared with investigator’s choice of standard single-agent chemotherapy (including eribulin, vinorelbine, gemcitabine, or capecitabine) in patients with HR+/HER2- breast cancer who had previously received one or two lines of systemic chemotherapy and were either ineligible for surgery or had metastatic disease (61). This evidence concerns the gene HR and breast carcinoma.